Peroxovanadium Compounds Research Articles

Health Benefits of Vanadium and Its Potential as an Anticancer Agent.

Vanadium compounds have been known to have beneficial therapeutic properties since the turn of the century, but it was not until 1965 when it was discovered that those effects could be extended to treating cancer. Some vanadium compounds can combat common markers of cancer, which include metabolic processes that are important to initiating and developing the phenotypes of cancer. It is appropriate to consider vanadium as a treatment option due to the similarities in some of the metabolic pathways utilized by both diabetes and cancer and therefore is among the few drugs that are effective against more than one disease. The development of vanadium compounds as protein phosphatase inhibitors for the treatment of diabetes may be useful for potential applications as an anticancer agent. Furthermore, the ability of vanadium to redox cycle is also important for biological properties and is involved in the pathways of reactive oxygen species. Early agents including vanadocene and peroxovanadium compounds have been investigated in detail, and the results can be used to gain a better understanding of how some vanadium compounds are modifying the metabolic pathways potentially developing cancer. Considering the importance of coordination chemistry to biological responses, it is likely that proper consideration of compound formulation will improve the efficacy of the drug. Future development of vanadium-based drugs should include consideration of drug formulation at earlier stages of drug development.

Insulin Signalling: The Inside Story.

Insulin signalling begins with binding to its cell surface insulin receptor (IR), which is a tyrosine kinase. The insulin receptor kinase (IRK) is subsequently autophosphorylated and activated to tyrosine phosphorylate key cellular substrates that are essential for entraining the insulin response. Although IRK activation begins at the cell surface, it is maintained and augmented following internalization into the endosomal system (ENS). The peroxovanadium compounds (pVs) were discovered to activate the IRK in the absence of insulin and lead to a full insulin response. Thus, IRK activation is both necessary and sufficient for insulin signalling. Furthermore, this could be shown to occur with activation of only the endosomal IRK. The mechanism of pV action was shown to be the inhibition of IRK-associated phosphotyrosine phosphatases (PTPs). Our studies showed that the duration and intensity of insulin signalling are modulated within ENS by the recruitment of cellular substrates to ENS; intra-endosomal acidification, which promotes dissociation of insulin from the IRK; an endosomal acidic insulinase, which degrades intra-endosomal insulin; and IRK-associated PTPs, which dephosphorylate and, hence, deactivate the IRK. Therefore, the internalization of IRKs is central to insulin signalling and its regulation.

The Canadian Diabetes Association names Dr. Barry I. Posner as the 2015 Clinical & Scientific Section Lifetime Achievement Award Recipient.

The Canadian Diabetes Association names Dr. Barry I. Posner as the 2015 Clinical & Scientific Section Lifetime Achievement Award Recipient.

Synthesis, Structure, and Physiological Effects of Peroxovanadium(V) Complexes Containing Amino Acid Derivatives as Ancillary Ligands

Abstract We have synthesized and structurally characterized novel peroxovanadium(V) compounds containing amino acid derivatives as ancillary ligands; N-(4-imidazolylmethyl)-l-alanate (imala) and N-(4-imidazolylmethyl)-l-phenylalanate (imphe). The structure of the imala complex was determined using X-ray crystallography. These compounds stimulated the proliferation of H4IIEC3 rat hepatoma cells at low doses but were cytotoxic at high doses. They also exhibited insulin-mimetic effects.

Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions

In the recent past the standard treatment of kala-azar involved the use of pentavalent antimonials Sb(V). Because of progressive rise in treatment failure to Sb(V) was limited its use in the treatment program in the Indian subcontinent. Until now the mechanism of action of Sb(V) is not very clear. Recent studies indicated that both parasite and hosts contribute to the antimony efflux mechanism. Interestingly, antimonials show strong immunostimulatory abilities as evident from the upregulation of transplantation antigens and enhanced T cell stimulating ability of normal antigen presenting cells when treated with Sb(V) in vitro. Recently, it has been shown that some of the peroxovanadium compounds have Sb(V)-resistance modifying ability in experimental infection with Sb(V) resistant Leishmania donovani isolates in murine model. Thus, vanadium compounds may be used in combination with Sb(V) in the treatment of Sb(V) resistance cases of kala-azar.

Oxidative Desulfurization of Fuels Catalyzed by V2O5in Ionic Liquids at Room Temperature

An extraction and catalytic oxidation desulfurization (ECODS) system composed of V2O5, 30 wt % H2O2 and 1-butyl-3-methylimidazolium tetrafluoroborate ([Bmim]BF4) as the basic experiment was used for the removal of DBT from the model oil at moderate temperature (30 °C). In the reaction process, V2O5 was oxidized by H2O2 into peroxovanadium compounds. Meanwhile, the sulfur-containing compounds, such as benzothiophene (BT), dibenzothiophene (DBT), and 4,6-dimethyldibenzothiophene (4,6-DMDBT), were extracted into ionic liquid (IL) from the model oil and oxidized into their corresponding sulfones by peroxovanadium compounds. The reactivity of sulfur-containing compounds in the ECODS followed this order: DBT > BT > 4,6-DMDBT. In the case of ECODS, the sulfur removal of DBT can reach 98.7%, which was superior to that of the simple extraction with IL (16.5%) or the catalytic oxidation (2.8%). This ECODS system could be recycled seven times without a significant decrease in activity.

Kinetics of Inhibition of Rabbit Intestine Alkaline Phosphatase by Heteroligand Peroxo Complexes of Vanadium(V) and Tungsten(VI)

The present work was undertaken to examine and compare some biologically important properties of peroxo compounds of V(V) and W(VI) containing biogenic species as ancillary ligand. New anionic peroxovanadate(V) complex of the type Na[VO(O(2))(2)(triglycine)].3H(2)O (pV1) and a molecular peroxotungstate(VI) [WO(O(2))(2)(triglycine)].3H(2)O (pW1) were synthesized and characterized for the purpose and their stability in solution was ascertained. Studies on kinetics of inhibition of alkaline phosphatase activity by the newly synthesized compounds and series of dipeptide and amino acid containing peroxo complexes of vanadium and tungsten synthesized previously by us viz., Na[VO(O(2))(2)(gly-gly)(H(2)O)].H(2)O (gly-gly = glycyl-glycine), Na[VO(O(2))(2)(asn)].H(2)O (asn = asparagine), Na[VO(O(2))(2)(gln)].H(2)O (gln = glutamine), and [WO(O(2))(2)(gly-gly)(H(2)O)].3H(2)O, revealed that each of these species is a potent mixed-type inhibitor of the enzyme. Significant difference was noted between the peroxovanadium (pV) and peroxotungsten (pW) compounds in terms of their oxidant activity with reduced glutathione.

New peroxovanadium compounds containing biogenic co-ligands: synthesis, stability and effect on alkaline phosphatase activity

A set of new diperoxovanadate(V) complexes with the dipeptides glycyl–glycine or glycyl–leucine as ancillary ligands of the type, A[VO(O2)2(peptide)(H2O)] · H2O, A = Na or K have been synthesized and characterized by elemental analysis, thermal analysis, magnetic susceptibility and spectral studies. The complexes contain side-on bound peroxo groups and a dipeptide zwitterion as co-ligand, binding the metal center unidentately through O (carboxylate) atom. The compounds are highly stable toward decomposition in solutions of acidic as well as physiological pH and serve as weak substrates to catalase, undergoing degradation in the presence of the enzyme at a rate much slower than H2O2. The compounds stoichiometrically oxidize GSH to GSSG. On comparing the GSH oxidizing ability of these compounds with those of previously reported peroxotungsten compounds containing similar co-ligands, a significant difference was noted. The compounds induce a strong inhibitory effect on alkaline phosphatase activity with a potency higher than that of the free peptides, vanadate, or peroxovanadate.

Vanadate-induced cell death is dissociated from H2O2 generation

Vanadium is an environmentally toxic metal with peculiar and sometimes contradictory cellular effects. It is insulin-mimetic, it can either stimulate cell growth or induce cell death, and it has both mutagenic and antineoplastic properties. However, the mechanisms involved in those effects are poorly understood. Several studies suggest that H(2)O(2) is involved in vanadate-induced cell death, but it is not known whether cellular sensitivity to vanadate is indeed related to H(2)O(2) generation. In the present study, the sensitivity of four cell lines from different origins (K562, K562-Lucena 1, MDCK, and Ma104) to vanadate and H(2)O(2) was evaluated and the production of H(2)O(2) by vanadate was analyzed by flow cytometry. We show that cell lines very resistant to H(2)O(2) (K562, K562-Lucena 1, and Ma104 cells) are much more sensitive to vanadate than MDCK, a cell line relatively susceptible to H(2)O(2), suggesting that vanadate-induced cytotoxicity is not directly related to H(2)O(2) responsiveness. In accordance, vanadate concentrations that reduced cellular viability to approximately 60-70% of the control (10 mumol/L) did not induce H(2)O(2) formation. A second hypothesis, that peroxovanadium (PV) compounds, produced once vanadate enters into the cells, are responsible for the cytotoxicity, was only partially confirmed because MDCK cells were resistant to both vanadate and PV compounds (10 micromol/L each). Therefore, our results suggest that vanadate toxicity occurs by two distinct pathways, one dependent on and one independent of H(2)O(2) production.

Effect of preparation conditions on the ordering of structural elements in vanadium pentoxide xerogels

Vanadium(V) oxide xerogels with an ordered laminar structure are of considerable interest in modern inorganic chemistry [1]. They combine the ease of intercalation of inorganic ions [2] or organic molecules [3] into the interlayer space and the presence of a transition metal ions with variable oxidation states, giving rise to nonlinear electrical and, in some cases, magnetic characteristics. Hybrid inorganic‐organic materials based on xerogels of vanadium(V) oxide and its nanotubular forms [4] attract considerable attention due to their unique physical and unusual physicochemical and rheological properties, which enable their use as cathode materials for lithium batteries [5], chemical sensors [6], electrochromic materials [7], and catalysts [8]. Vanadium(V) oxide xerogels can be prepared by hydrolysis of organic derivatives of vanadic acid, by polycondensation of vanadates in an aqueous solution in an acid medium, and by decomposition of peroxovanadium(V) compounds upon dissolution of the crystalline oxide in hydrogen peroxide [1, 9, 11]. The mechanisms of these processes are essentially different; therefore, it is important to elucidate the structural features of the xerogels as a function of the preparation method. Small-angle X-ray scattering, which is a standard method for measuring the kinetics of gel condensation in solutions [10], can also be used rather efficiently to study the structural features of xerogels. This study reveals the correlation between the chemical prehistory and the structural organization of samples obtained. Complex analysis of small-angle X-ray scattering (SAXS) patterns of xerogel films synthesized by different methods was carried out for the first time and possible models for description of their structure were considered. Colloid solutions of vanadium(V) oxide for the formation of xerogel films were prepared by three procedures (table). According to method A, analytical grade crystalline V 2 O 5 (0.5 g) was dissolved in 15% H 2 O 2 (30 mL) by slow addition of V 2 O 5 powder to the hydrogen peroxide solution [11]. After the oxygen evolution ceased, the solution became yellow. Heating the solution to ~40°C gave a dark red solution, which was kept under ambient conditions for 7 days until a xerogel film formed. According to method B, the gel was obtained by hydrolysis of tert -butyl metavanadate VO(OC(CH 3 ) 3 ) 3 . The ester was synthesized [11] by refluxing a mixture of calcined vanadium(V) oxide with excess tert -butyl alcohol in the presence of a desiccant (silica gel) for 7 h. The resulting mixture was separated by distillation at 81°C . Hydrolysis was carried out by mixing the ester with an equal volume of water (an excess) for the preparation of bulk samples or under ambient conditions. In method C, polycondensation of V took place in an aqueous solution of sodium vanadate on acidification. A colloid solution of V 2 O 5 · n H 2 O was obtained by

Semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 activity exerts an antidiabetic action in Goto-Kakizaki rats.

In this study we have explored whether the bifunctional protein semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) represents a novel target for type 2 diabetes. To this end, Goto-Kakizaki (GK) diabetic rats were treated with the SSAO substrate benzylamine and with low ineffective doses of vanadate previously shown to have antidiabetic effects in streptozotocin-induced diabetic rats. The administration of benzylamine in combination with vanadate in type 2 diabetic rats acutely stimulated glucose tolerance, and the chronic treatment normalized hyperglycemia, stimulated glucose transport in adipocytes, and reversed muscle insulin resistance. Acute in vivo administration of benzylamine and vanadate stimulated skeletal muscle glucose transport, an effect that was also observed in incubated muscle preparations coincubated with adipose tissue explants or with human recombinant SSAO. Acute administration of benzylamine/vanadate also ameliorated insulin secretion in diabetic GK rats, and this effect was also observed in incubated pancreatic islets. In keeping with these observations, we also demonstrate that pancreatic islets express SSAO/VAP-1. As far as mechanisms of action, we have found that benzylamine/vanadate causes enhanced tyrosine phosphorylation of proteins and reduced protein tyrosine phosphatase activity in adipocytes. In addition, incubation of human recombinant SSAO, benzylamine, and vanadate generates peroxovanadium compounds in vitro. Based on these data, we propose that benzylamine/vanadate administration generates peroxovanadium locally in pancreatic islets, which stimulates insulin secretion and also produces peroxovanadium in adipose tissue, activating glucose metabolism in adipocytes and in neighboring muscle. This opens the possibility of using the SSAO/VAP-1 activity as a local generator of protein tyrosine phosphatase inhibitors in antidiabetic therapy.

MKP-1 as a target for pharmacological manipulations in PC12 cell survival

Dual specificity mitogen activated protein kinase phosphatase-1 (MKP-1) inactivates extracellular signal-regulated kinase (ERK), p38 and/or c-jun N-terminal protein kinase (JNK) by dephosphorylation via a negative feed-back loop. The aim of the present study was to assess the role of expression of MKP-1 and phosphorylation status of mitogen-activated protein kinases (MAPKs) in promoting cell survival in PC12 cells. We used FK506 and three different monoperoxovanadium complexes (mpVs) as pharmacological tools for manipulation of MKP-1 expression. Peroxovanadium compounds, known to be insulinomimetic agents and protein tyrosine phosphatase inhibitors, are cytotoxic to the cells, they activate JNK and down-regulate MPK-1. On the other hand, FK 506 has transient effect on ERK activation. However, when the agents are used in combination, ERK phosphorylation is prolonged and intensified, MKP-1 expression is increased, and cell survival is enhanced. The concomitant alterations observed in intensities and duration of phospho-ERKs and phospho-JNKs signals suggest that monoperoxovanadium complexes in combination with FK 506 enhance survival of PC12 cells by an induction of MKP-1 expression.

Peroxovanadium-mediated protection against murine leishmaniasis: role of the modulation of nitric oxide.

The phosphotyrosine phosphatase inhibitor bpV(phen) has the ability to markedly decrease the progression of leishmaniasis in vivo. Here, we have identified the mechanisms that are responsible for this protective effect. We report that two potent peroxovanadium (pV) compounds, bpV(phen) and bpV(pic), control progression of leishmaniasis in a similar manner by modulating NO-dependent microbicidal action. We observed that their injection can rapidly and transiently induce the expression of inducible NO synthase (iNOS) in livers of mice and enhance circulating nitrate levels. Treatment of mice with bpV(phen) or bpV(pic) completely controlled progression of leishmaniasis in an NO-dependent manner, since inhibition of iNOS with aminoguanidine completely reversed this pV-mediated protection. This NO-dependent pV-mediated protection was further demonstrated by the incapacity of bpV(phen)-treated Nramp-/-, iNOS-/- mutant mice to control Leishmania major infection. Using an air pouch model, we showed that bpV(phen) can strongly modulate secretion of L. major-induced pro-inflammatory molecules and neutrophil recruitment. In addition, we observed that bpV(phen) per se can strongly induce the expression of Th1 type cytokines over Th2 in spleens of animals. Overall, this study has allowed us to establish the in vivo functional and immunological events involved in pV-mediated protective mechanism against leishmaniasis and that NO plays a pivotal role in this process.

The insulin receptor kinase: modulation and therapeutic implications

Following the binding of insulin to its cell surface receptor there is rapid activation of the insulin receptor kinase (IRK), leading to autophosphorylation of the receptor on tyrosine residues and the capacity to tyrosine phosphorylate various cellular substrates. The peroxovanadium compounds (pVs) were shown to activate the IRK in the complete absence of insulin and correlatively activate the full insulin signalling cascade. Along with earlier studies on mutant IRKs, this observation indicated that IRK function is both necessary and sufficient for insulin signaling. IRK is rapidly internalized into the endosomal apparatus (ENs), where it remains activated for a significant time and is capable of entraining insulin signalling events. Thus, modulation of the IRK in ENs is an important means by which insulin signalling is influenced. In recent years, several endosomal processes were shown to regulate IRK activity. The presence in ENs of a relatively specific insulin protease (endosomal acidic insulinase (E...

The role of insulin dissociation from its endosomal receptor in insulin degradation

Mechanisms that terminate signals from activated receptors have potential to influence the magnitude and nature of cellular responses to insulin. The aims of this study were to determine in rat liver endosomes (the subcellular site of insulin signal termination) whether dissociation of insulin from its receptor was a pre-requisite for ligand degradation and whether the state of receptor phosphorylation influenced the dissociation and hence endosomal degradation of insulin and/or receptor recycling. Following in vivo administration of 125I-[A14]-insulin or analogues (native, X10 or H2, relative binding affinities 1:7:67) livers were removed and endosomes prepared. In the endosomal preparations a significantly greater percentage of both analogues were receptor-bound than native insulin with concomitantly less ligand degradation. When rats were injected with protein-tyrosine phosphatase inhibitors (peroxovanadium compounds bpV(phen) or bpV(pic)) before insulin, endosomal insulin receptor phosphotyrosine content, assessed by Western blotting, was increased as was receptor-bound 125I-[A14]-insulin, whilst insulin degradation was decreased. Peroxovanadiums also completely inhibited recycling of insulin receptors from endosomes. However, treatment of freshly isolated endosomes with acid phosphatase which completely dephosphorylated the insulin receptor, did not return the rate of insulin dissociation and degradation to control values, suggesting that peroxovanadium compounds elicit their effect on binding and degradation via a mechanism other than as protein-tyrosine phosphatase inhibitors. We conclude that promotion of sustained receptor binding decreases endosomal insulin degradation and extends the half-life of the activated endosomal receptor, which in turn would be expected to potentiate insulin signalling from this intracellular compartment.

Models for the active site of vanadium-dependent haloperoxidases: insight into the solution structure of peroxo vanadium compounds

A combined use of electrospray ionization-mass spectrometry (ESI-MS), 51V NMR spectroscopy and ab initio calculations has been proved to be a powerful tool for obtaining direct information of the structure and the chemistry of peroxo vanadates in solutions. The analysis of acid solutions containing monoperoxo vanadates showed the occurrence of exchange reactions between solvent molecules in the coordination sphere of the metal. On the other hand, bisperoxo vanadates appear to be less prone to coordinate more than one water or alcohol molecule. The bisperoxo complex [VO 5] − in the presence of histidine and histidine-like ligands, at near neutral conditions, has been studied. Coordination of one and two molecules of ligand is observed affording [VO 5L] − and [VO 5L 2] −, respectively. Characterization of these species has been obtained by MS n experiments, which allowed us to distinguish specific fragmentations of the peroxidic moiety.

Different Forms of Vanadate on Sugar Transport in Insulin Target and Nontarget Cells.

The effects of several vanadates (ie, orthovanadate, pervanadate, and two stable peroxovanadium compounds) on basal and insulin-stimulated 2-DG transport in insulin target and nontarget cell lines are reported, herein. In nontarget cells, exposure to vanadates (5 × 10−6 to 10−4 mol/L) resulted in 2-DG transport stimulatory responses similar to those observed in 2-DG transport post exposure to 667 nmol/L insulin alone, or insulin in combination with vanadates. In 3T3-L1 adipocytes and L6 myotubes, exposure to a vanadate compound or 67 nmol/L insulin, stimulated 2-DG transport dramatically. Again, this effect on stimulated transport was similar to 2-DG transport post-treatment with the effective vanadates in combination with insulin. While pervanadate or stable peroxovanadates stimulated 2-DG transport at 10−5 to 10−6 mol/L, orthovanadate up to 10−4 mol/L was not effective in stimulating 2-DG transport in any of the cell lines tested. The data indicate that the various peroxovanadates are clearly superior insulin mimetics while a more limited insulin mimesis is observed with orthovanadate over a wide variety of cell types.

Transdermally delivered peroxovanadium can lower blood glucose levels in diabetic rats

The element vanadium can have insulin mimetic properties and therefore has been suggested as a possible therapeutic agent for treatment of diabetes. A series of peroxovanadium compounds that are more potent at lowering blood glucose levels than sodium metavanadate, sodium orthovanadate and vanadyl sulfate have recently been synthesized. These compounds probably will not be orally active so transdermal administration is a potential option. A patch containing either the peroxovanadium compound [VO(O 2) 2 1–10 phenanthroline], abbreviated bpV(phen), or placebo was placed on the back of streptozotocin induced diabetic rats and was delivered either passively (16 h) or iontophoretically (0.5 mA/cm 2 for 4 h). Blood samples were analyzed for glucose and vanadium levels. Mean blood glucose levels were 83±1% and 109±1% of the starting values for animals iontophoretically treated with bpV(phen) and vehicle, respectively. The compound’s insulin mimetic properties were evident within 60 min of current initiation. Blood glucose levels were reduced to 74±14% of the original level after 16 h of passive treatment. The compound was ineffective when fed to animals. Transdermal delivery of bpV(phen) resulted in significantly greater blood levels of vanadium than the orally delivered compound ( P<0.05). Overall these experiments demonstrate that peroxovanadium delivered through the skin can lower blood glucose levels in rats. Further experiments are warranted to better characterize the nature of the response and to determine the potential for using these compounds in humans.

SYNTHESIS AND CHARACTERIZATION OF NEW OXODIPEROXOVANADATE COMPLEXES CONTAINING COORDINATED AMINOACIDS

The study of peroxovanadium compounds has received renewed attention since the discovery of their insulin mimetic properties and of the vanadium bromoperoxidase enzyme which catalyzes the oxidation of halides by hydrogen peroxide. This work presents the synthesis and characterization of three novel oxodiperoxovanadium complexes, K n [VO(O2)2AA] 2H2O, where AA = L-asparagine(l), L-phenylglycine(2), D, L-homocystine(3). The products were synthesized by the reaction of V2O5, with the amino acid and H2O2 at room temperature. The compounds obtained are yellow, soluble in water and insoluble in organic solvents. They show remarkable hygroscopic character and are light and temperature sensitive. IR and UV-VIS spectra of the compounds show the typical oxo and diperoxo bands (νv = o = 970 cm−1, νvo-o = 870cm−1, νv-O2 = 630, 525 cm−1, ⋋ ≅320nm). The ligand bonding properties were determined on the basis of electric conductivity and spectroscopic data (IR, 1H NMR) as well as elemental analysis.

Peroxovanadium compounds as inhibitors of angiogenesis.

Angiogenesis is a complex process that involves the activation of endothelial cells through the triggering of several intracellular signaling pathways including those involving tyrosine phosphorylation. In the present study, we analyzed the angiogenic properties of two phosphotyrosyl phosphatase (PTP) inhibitors that are composed of a peroxovanadium core containing different ancillary ligands. In cell monolayer and 3D culture systems examined in this study, the administration of potassium bisperoxo(1,10-phenanthroline)oxovanadate(V) [bpV(phen)] or potassium bisperoxo(pyridine-2-carboxylato)oxovanadate(V) [bpV(pic)], but not oxovanadiums, interfered markedly with endothelial cell growth, organization, and terminal differentiation. This effect was dependent upon both the compound's dose and the nature of the ancillary ligand. Rat aortic ring assay showed a significant inhibition by low dose of bpV(phen) on cell migration. In addition, a chick embryo angiogenesis assay demonstrated that bpV(phen) is a potent inhibitor of angiogenesis. Among PTP inhibitors, bpV(phen) had powerful angiostatic properties at a low concentration.